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Despite major advances in the treatment of heart failure due to systolic impairment, therapeutic approaches have fallen short of addressing the cause of the problem; injury of the 
mammalian heart leads to irreversible loss of contractile myocardial 
tissue which is incapable of regeneration. At the turn of the millen-
nium heart failure was widely identified as an emerging epidemic1. 
To date, 5.6 million patients in the United States alone and 23 mil-
lion worldwide are suffering from heart failure, with 50% dying 
within 5 yr after being diagnosed2,3. Current treatment is limited to 
ameliorating symptoms and slowing the natural progression of the 
disease but fails to compensate for the loss of contractile myocar-
dium postinjury.
Regenerative medicine may hold the key to effectively treating 
heart failure by using stem-cell-derived cardiovascular cells and 
tissues to restore full contractile function4,5. Of all stem cell types, 
human pluripotent stem cells such as hESCs and induced pluripo-
tent stem cells have the greatest potential for forming cardiovascular 
tissues, reliably giving rise to cardiomyocytes (CMs)6–8, endothelial 
cells9,10, smooth muscle cells11 and more recently epicardial and 
endocardial-like cells12–15 under chemically defined conditions. 
Furthermore, hESC-derived CMs have been successfully used 
to remuscularize infarcted rat8 and guinea pig16,17 hearts, result-
ing in electrical integration and preserving cardiac function. The 
clinical potential of this technology has also been demonstrated 
in non-human primate models, where transplantation of human 
or monkey pluripotent stem cell-derived CMs resulted in sub-
stantial remuscularization of the infarcted heart and restoration of 
cardiac function18–20.
While mammalian heart regeneration has made progress, hur-
dles remain, such as relative immaturity of transplanted cells, sub-
optimal graft retention, insufficient cellular proliferation and a small 
graft size. In  vitro, human pluripotent stem cell (hPSC)-derived 
CMs derived from most protocols at best resemble CMs found 
in a first trimester fetus, which may limit the functional benefits 
post-transplantation21. To date, little attention has been devoted to a 
supportive cell type that would promote maturity of hESC-derived 
CMs and increase the graft size post-transplantation in vivo.
In early mammalian heart development, the epicardium plays a 
pivotal role as a progenitor cell source and provides trophic support 
for developing CMs. Because the epicardium gives rise to cardiac 
fibroblasts and coronary smooth muscle cells, it is essential for the 
formation of a functioning connective tissue and coronary vascula-
ture22,23. Moreover, epicardium-derived cells (EPDCs) are essential 
for cardiac proliferation and compaction24–26 and have been reported 
to promote CM maturation27–29. Given their trophic role in heart 
development, we hypothesized that epicardial cells could promote 
CM maturation and contractility in hESC-based three-dimensional 
(3D)-EHTs in vitro and enhance engraftment and maturity leading 
to potential functional benefits when cotransplanted with hESC-
derived CMs in vivo.
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The epicardium and its derivatives provide trophic and structural support for the developing and adult heart. Here we tested 
the ability of human embryonic stem cell (hESC)-derived epicardium to augment the structure and function of engineered heart 
tissue in vitro and to improve efficacy of hESC-cardiomyocyte grafts in infarcted athymic rat hearts. Epicardial cells markedly 
enhanced the contractility, myofibril structure and calcium handling of human engineered heart tissues, while reducing pas-
sive stiffness compared with mesenchymal stromal cells. Transplanted epicardial cells formed persistent fibroblast grafts in 
infarcted hearts. Cotransplantation of hESC-derived epicardial cells and cardiomyocytes doubled graft cardiomyocyte prolifer-
ation rates in vivo, resulting in 2.6-fold greater cardiac graft size and simultaneously augmenting graft and host vascularization. 
Notably, cotransplantation improved systolic function compared with hearts receiving either cardiomyocytes alone, epicardial 
cells alone or vehicle. The ability of epicardial cells to enhance cardiac graft size and function makes them a promising adjuvant 
therapeutic for cardiac repair.
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We report here that hESC-derived epicardium promotes 
the development of three-dimensional engineered heart tissues 
(3D-EHTs) in vitro and cardiac grafts in vivo via CM maturation, 
proliferation and contraction. In the infarcted heart, hESC-derived 
epicardial cells (hESC-EPIs) also increase endogenous neo-vessel 
development and enhance hESC-CM proliferation and subsequent 
maturation, thus creating larger grafts of human myocardium that 
further enhance ventricular function. By recapitulating key devel-
opmental steps, the epicardium augmented CM function, making it 
a promising adjuvant therapy in regenerative medicine.
Results
hESC-EPIs promote CM maturation in 3D-EHTs. We first gen-
erated hESC-derived green fluorescent protein (GFP)-transgenic 
epicardial cells and wild-type (WT) CMs as previously described8,12 
(Fig. 1a,b). Epicardial cells expressed epicardial and epithelial mark-
ers, WT1 and pan-cytokeratin, but no mesenchymal markers such 
as vimentin after their derivation in vitro12,30. The functionality of 
epicardial cells was initially demonstrated through differentiating 
them to cardiac fibroblasts in vitro under chemically defined condi-
tions that included VEGF and FGF. At the end of this differentiation 
protocol they expressed the fibroblast and mesenchymal markers, 
S100A4, DDR2 and vimentin, but lost their epithelial character 
indicating successful epithelial-to-mesenchymal transition (EMT). 
During epicardial to fibroblast differentiation, WT1 was downreg-
ulated while the fibroblast marker S100A4 was gradually upregu-
lated. (Supplementary Fig. 1a–e).
Next, we tested the utility of epicardial cells in the context of 
3D-EHTs. We incorporated epicardial cells along with hESC-CMs 
into collagen-based 3D-EHTs31, which developed for 14 d under 
passive stress before they were subjected to histological and func-
tional assessment (Fig. 1c,d). To investigate the potency of epicardial 
cells in 3D-EHTs, we compared them with constructs containing: 
(1) CMs alone; (2) CMs and hESC-derived mesenchymal cells; and 
(3) CMs and primary human mesenchymal stromal cells (MSCs) 
from bone marrow. Epicardial cells as well as primary mesenchymal 
cells had the strongest effects on tissue remodeling and compaction, 
whereas tissues containing high-purity CMs alone demonstrated 
minimal compaction (Fig. 1e–g).
Whilst in the tissues, hESC-EPIs underwent EMT as indicated by 
the increase in expression of vimentin and decrease in pan-cytoker-
atin, comparing constructs after 7 d and 14 d of development. In this 
context, epicardial derivates have previously been termed EPDCs23. 
EPDCs are positive for vimentin and S100A4, indicative of a fibro-
blast phenotype (Supplementary Fig. 2a–c).
To determine the state of CM maturity, histological sections of 
the 3D-EHTs were stained for sarcomeric proteins, and the sarco-
mere length, cell diameter, cell sectional area and myofibril alignment 
were quantified. HESC-EPIs promoted the greatest sarcomere length, 
cell diameter, cell sectional area and myofibril alignment, which cor-
relate with CM maturation, compared with primary MSCs, hESC-
derived MSCs or CM alone (Fig. 1h–j and Supplementary Fig. 3a). 
3D-EHTs containing hESC-EPIs and primary MSCs exhibited the 
greatest degree of sarcomeric organization (Supplementary Fig. 3b). 
Furthermore, constructs containing hESC-EPIs expressed more con-
nexin 43, a marker of electrical connectivity between CMs, compared 
with the other groups (Supplementary Fig. 2d, e). Gene expression 
by quantitative PCR with reverse transcription (RT–qPCR) dem-
onstrated trends consistent with increases in the ratios of adult/fetal 
isoforms of contractile proteins (MYH7/MYH6, MYL2/MYL7 and 
TNNI3/TNNI1), all indicators of CM maturity (Supplementary Fig. 4). 
In conclusion, hESC-EPIs replicate key steps of early embryonic heart 
development in 3D-EHTs, resulting in increased CM maturation.
hESC-EPIs enhance functional maturation of 3D-EHT. We 
next tested whether the beneficial effects of hESC-EPIs observed 
histologically also translated to an increase in contractility. EHT 
constructs were transferred to a myograph with a length controller 
and a force transducer (Supplementary Fig. 5a); constructs contain-
ing CMs and hESC-MSCs or primary MSCs or hESC-EPIs exhibited 
a Frank–Starling relationship, where twitch force increased linearly 
with increasing preload. In line with the histological finding that 
high-purity CMs alone do not result in efficient tissue remodeling, 
CM maturation or electrical connectivity, we did not observe coor-
dinated contraction or measurable force production in 3D-EHTs 
containing CMs alone. Constructs containing hESC-EPIs produced 
the greatest total force amongst the four groups. Additionally, EHTs 
containing hESC-EPIs showed the greatest increase in active force 
production with increasing strain (that is, the greatest contractil-
ity) compared with primary MSCs and hESC-MSCs (Fig. 2a and 
Supplementary Fig. 5b). At the same time, 3D-EHTs containing 
hESC-EPIs produced the least passive force compared with primary 
MSCs or hESC-MSCs, which would correspond to a more compli-
ant tissue with better relaxation potential during diastole (Fig. 2b).
When assessing the Ca2+ handling of the constructs, those 
containing hESC-EPIs and primary MSCs accounted for the 
most mature Ca2+ transients (Fig. 2c,d). Constructs contain-
ing EPDCs had more rapid Ca2+ release and Ca2+ decay com-
pared with those with primary MSCs (Fig. 2e and Supplementary 
Fig. 5c, d). Constructs containing hESC-MSCs displayed irregular 
and broad Ca2+ transients, reflecting less coordinated beating. In 
those containing CM-only, no coordinated Ca2+ transients were 
detectable, but rather asynchronous contraction of single non-
connected CMs was observed, which translated to noise in multi-
cellular regions of interest.
Next, we tested whether the ability of epicardial cells to promote 
3D-EHT function is independent of the parental hESC line. We 
generated EHTs where CMs and EPDCs were differentiated from 
the same H9 line, as well as with CMs from H9 cells and EPDCs 
from RUES2 hESCs. In both contexts, the EPDC-containing EHTs 
showed superior contractility and Ca2+ dynamics compared with 
EHTs made with hESC-MSCs or primary MSCs. These experiments 
demonstrated that enhancement of EHT function by EPDCs is a 
general attribute of epicardial cells and not a line-dependent artifact 
(Supplementary Figs. 6a,b and 7a–d).
Furthermore, in a separate experiment we determined the 
nature of the non-CM population obtained on differentiation of 
high-purity CMs by flow cytometry using markers previously 
described32. We found positivity for THY1 and PDGFR-β and to 
a minor degree for CD31 and NKX2.5 in this cTnT-negative cell 
population (Supplementary Fig. 8). Overall, this demonstrated a 
mesenchymal and fibroblast-like nature to these non-CMs and was 
comparable between RUES2- and H9-derived cells.
In conclusion, hESC-EPIs promote functional maturation of 
3D-EHT. These findings encouraged us to explore their use in vivo 
as an adjunct to CM transplantation for cardiac repair.
Epicardial cells engraft and differentiate in the myocardial 
infarct. To assess the response of hESC-EPIs to engraftment 
in vivo we performed a series of pilot transplants into the infarct 
zone of athymic rats (Supplementary Fig. 9a). Because most 
non-myocytes that are transplanted into the heart rapidly die33, 
we subjected the epicardial cells to heat shock and a prosurvival 
cocktail (PSC) of anti-apoptotic and anti-necrotic factors. At 
7 d post-transplantation we found small grafts in 3 of 4 animals 
receiving 2 × 106 cells and larger grafts in all 4 animals receiving 
4 × 106 cells (Supplementary Fig. 9b, c). To maximize survival at 
28 d post-transplantation, we delivered 6 × 106 cells and found large 
grafts in 6 of 6 animals (Supplementary Fig. 9d), indicating that 
the grafts survive long term. We confirmed in a separate experi-
ment that delivery with heat shock + PSC is required for engraft-
ment of epicardial cells (Supplementary Fig. 10a–c). Conversely, 
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Fig. 1 | Generation and maturation of 3D-EHts using hESC-EPIs and CMs. a, Epicardial cells derived from hESCs expressing the epicardial markers WT1 
and TCF21. Scale bar, 50 μm. b, Purity of epicardial cells and CMs by flow cytometry. Control groups represent secondary and isotype antibodies for 
epicardial cells and CMs, respectively. Flow cytometric analysis was independently repeated three times with similar results. c, Schematic of experimental 
design. Epicardial cells and CMs were derived from hESCs and cocultured in 3D-EHT. d, Schematic of 3D-EHT using hESC-EPIs and CMs. e,f, Compaction 
(e) and ultrastructure (f) of 3D-EHT containing CMs alone, CM + hESC-MSC, CM + Primary MSC or CM + hESC-EPI. Scale bars, 2.5 mm and 25 μm. a,e,f, 
Experiments were independently repeated nine times with similar results. g–j, Quantification of tissue remodeling (g), sarcomeric length (h), cell diameter 
(i) and cell sectional area (j). Mean values; error bars represent s.d. Two-sided P values were calculated using a one-way ANOVA with post-hoc correction 
for multiple comparisons. CM alone, CM + hESC-MSC, CM + Primary MSC and CM + hESC-EPI, n = 9, 9, 8, 9 constructs, generated independently and 
measured on 3 different days. D, day; FL4-H and PE-A, fluorescence channels.
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Fig. 2 | hESC-EPIs promote contractility and Ca2+ handling of 3D-EHts. a, Active force generation of 3D-EHT containing CMs alone,  
CM + hESC-MSC, CM + Primary MSC or CM + hESC-EPI. Displayed are the Frank–Starling curve of active force production and the slope of the  
generated curve, respectively. b, Passive force of 3D-EHT containing CMs alone, CM + hESC-MSC, CM + Primary MSC or CM + hESC-EPI.  
Displayed are the curve of passive force production and the slope of the generated curve, respectively. c, Representative Ca2+ traces of 3D-EHT.  
d, Overlay of representative Ca2+ curves. e, Slope of Ca2+ upstroke and Ca2+ downstroke. Mean values; error bars represent s.d. Dotted lines  
represent 95% confidence intervals. Two-sided P values were calculated using a one-way ANOVA with post-hoc correction for multiple comparisons.  
CMs alone, CM + hESC-MSC, CM + Primary MSC and CM + hESC-EPI, n = 9, 9, 8 and 9 constructs, generated independently and measured on  
3 different days. n.a., not applicable; NS, not significant.
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epicardial cell transplantation in NOD scid gamma mice, without 
heat shock + PSC, demonstrated no detectable graft formation at 
28 d (Supplementary Fig. 11a–c).
At 7 d post-transplantation the EPDCs coexpressed pan-
cytokeratin and vimentin, indicating ongoing EMT. At 28 d post-
transplantation EMT was essentially complete, with all grafted cells 
expressing vimentin and almost no detectable expression of pan-
cytokeratin (Supplementary Fig. 9e,f). A small subpopulation of 
grafted vimentin-positive cells coexpressed WT1 on day 7 and day 
28. This reflects the human fetal heart, where activated vimentin+ 
epicardial cells invade the compact myocardium with a subpopula-
tion retaining WT1 expression (Supplementary Fig. 9g,g’). At 28 d 
the grafted epicardial cells expressed S100A4, suggesting a fibro-
blast phenotype, whereas they neither expressed SM22α nor inte-
grated into blood vessel walls, (Supplementary Fig. 12a,b). Grafted 
cells were negative for the cardiac marker α-actinin and the endo-
thelial marker human lectin (Supplementary Fig. 12c–e). Taken 
together, these data indicate that EPDCs differentiate into cardiac 
fibroblast-like cells with no formation of CMs, endothelial cells or 
smooth muscle cells.
Because EPDCs readily form smooth muscle cells in  vitro, we 
hypothesized that the infarct environment inhibited this differen-
tiation pathway. To test this, we delivered hESC-EPIs in PSC onto 
the chorionic vasculature of chick embryos. After 5 d the human 
EPDCs had integrated into the walls of host vessels and expressed 
SM22α (Supplementary Fig. 13a–c). Thus, epicardial cells are mul-
tipotent and in an embryonic environment readily differentiate into 
vascular smooth muscle, whereas in the adult infarct they form 
fibroblast-like cells.
Cotransplantation of epicardial cells and CMs augments micro-
vascular density. The long-term persistence of hESC-EPIs in 
infarcted hearts led us to hypothesize that these cells would exhibit 
a trophic effect on grafted hESC-CMs and the host myocardium. 
To test this, we performed a cotransplantation study where 4 
groups of athymic rats received an injection of 5 × 106 hESC-EPIs, 
10 × 106 hESC-derived CMs, the combination of both (EPI + CM: 
5 × 106 hESC-EPIs plus 10 × 106 CMs) or vehicle control (PSC; 
Fig. 3a). At 4 weeks post-transplantation no difference in infarct 
size was found between the groups, ruling out effects on infarct 
scar healing (Fig. 3b,c).
To assess whether cell transplantation had an effect on host vessel 
recruitment, we quantified the microvascular density in the cardiac 
grafts, the infarct zone and the non-injured border zone (Fig. 3d). 
Microvascular density was significantly increased in cardiac grafts 
of animals that were cotransplanted with epicardial cells and CMs. 
Furthermore, erythrocytes were readily detectable in the lumens 
of the vessels, indicating perfusion via the coronary circulation 
(Fig. 3e and Supplementary Fig. 14a). We also observed an increase 
in microvascular recruitment in the infarct zone and in the non-
injured border zone of the infarct, which was highest in EPI + CM, 
followed by CM, then EPI and finally vehicle control (Fig. 3f,g). 
To assess the timing of microvascular sprouting we made use of our 
pilot trial data set, and demonstrated that epicardial cells alone led 
to a significant increase in microvascular density in the infarct and 
border zones by day 28 but not by day 7 post-transplantation, indi-
cating delayed angiogenic effects (Supplementary Fig. 14b–e).
To address the maturity of neo-vessels we also screened the 
three areas of interest for presence of smooth muscle cell-coated 
arteries. Vessels containing SM22α+ mural cells were abundant in 
the infarct zone and the border zone of all groups. However, when 
assessing their presence within cardiac grafts we observed smooth 
muscle cell-coated vessels in the EPI + CM group but not in the 
CM-alone group, suggesting that epicardial cells promote smooth 
muscle encoatment and vascular maturation within the graft 
(Supplementary Fig. 14f–k). Absence of costaining for SM22α and 
human mitochondria further confirmed that the smooth muscle 
coats were rat-derived, and that epicardial cells were also not able 
to differentiate to smooth muscle cells in the infarct zone in the 
presence of CMs (Supplementary Fig. 14l). In summary, hESC-EPIs 
create a more highly vascularized cardiac graft, and microvascular 
density surrounding scar and border zones, which should promote 
a more favorable niche for hESC-CM engraftment and function.
Cotransplantation promotes cardiac graft size, proliferation and 
maturity. We next assessed the effects of epicardial cells on the 
cardiac grafts. Given the trophic effects of epicardial cells on CMs 
in vitro, we first investigated whether cotransplantation would affect 
cardiac graft size. Cardiac grafts were readily identified with anti-
bodies directed against β-MHC (MYH7; whereas rat CMs predomi-
nantly express α-MHC/MHY6) and coexpressed α-actinin. Cardiac 
grafts were 2.6-fold larger when CMs were cotransplanted with 
epicardial cells, compared with CMs alone, averaging 3.9 ± 1.6% of 
the left ventricle versus 1.5 ± 0.9% of the left ventricle, respectively 
(Fig. 4a,b and Supplementary Fig. 14m).
Because epicardial cells secrete growth factors for CMs dur-
ing development, we hypothesized that epicardial cells augmented 
graft size via increased CM proliferation. All rats in this phase of 
the study were pulsed with the thymidine analog, BrdU, on 1, 3, 
7 and 14 d post-cell delivery. To determine cumulative prolifera-
tion rates in the grafts we stained with antibodies directed against 
BrdU and the human-specific cardiac marker β-MHC. The pro-
liferative index of β-MHC-positive cells was twofold higher in 
animals that received the combination of hESC-EPIs and CMs 
(8% ± 1.4%) compared with CMs alone (4 ± 0.9%, P < 0.0001; 
Fig. 4c,d). Conversely, there was no difference in the prolifera-
tive index of vimentin-positive EPDCs in animals receiving epi-
cardial cells alone or epicardial cells with CMs (Supplementary 
Fig. 15a,b). Taking the graft CM BrdU rates as daily averages of 
DNA synthesis, and assuming that the cell cycle lasts 24 h, hESC-
CM graft expansion can be calculated for each group. For 28-day 
grafts, control expansion would be 1.04 × 1028, or 3.0-fold expan-
sion, while in cotransplantation studies it would be 1.08×1028, or 
8.6-fold expansion. This predicts a 2.9-fold difference in graft size, 
which is quite close to our observed 2.6-fold difference. Thus, 
although we cannot rule out a role for increased graft survival, 
these data indicate that enhanced CM proliferation is a major 
driver for the increased CM graft size observed with hESC-EPI 
cotransplantation.
Given the epicardial effects on CM maturation in  vitro, we 
assessed the sarcomere length of the cardiac grafts. In line with 
our findings in  vitro, CMs that were cotransplanted with epicar-
dial cells exhibited a greater sarcomeric length and cell diameter as 
well as a 77% larger cell sectional area (Fig. 4f–h) than those that 
were transplanted alone, indicative of a more mature phenotype. 
Additionally, we demonstrated that cotransplantation of CMs with 
epicardial cells leads to an isoform switch from ssTnI to cTnI in 
cardiac grafts (Fig. 4e).
As cardiac fibrosis impedes structural integration of grafts and 
host34, we were concerned that epicardial cell-derived fibroblasts 
might interfere with gap junctions between graft and host CMs. 
To investigate this, we performed combined immunostaining for 
β-MHC, cTnT and the gap junction protein connexin 43. Gap junc-
tions between graft and host were seen in multiple areas across 
all animals, demonstrated by connexin 43 expression between 
neighboring human and rat CMs (Fig. 4i). While epicardial cells 
themselves can express connexin 43 (refs. 35,36), the gap junctions 
identified in our study were predominantly between CMs. In con-
clusion, hESC-EPIs promote cardiac graft size, in part through pro-
liferation, and enhance maturation/myofibril development while 
still permitting structural integration of grafted CMs with the recip-
ient myocardium.
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Cotransplantation promotes cardiac function. To assess the 
functional effects of cardiac grafts on global host heart function, 
we performed cardiac ultrasound on all animals before infarc-
tion, immediately before cell injection and after 28 d follow-up. 
The ultrasound scans (A.M.) and their interpretations (J.B. and 
F.W.) were performed by investigators who were blinded to the 
treatment to prevent bias. All groups exhibited comparable left 
ventricular dilation and decline in left ventricular function after 
infarction, consistent with the histological finding of comparable 
infarct sizes (Fig. 5a–c and Supplementary Table 1). Compared with 
their pre-injection (postinfarction) baseline values, the vehicle con-
trol group displayed a 9 ± 5.4% decline in fractional shortening by 
4 weeks after injection, indicating a progression toward heart failure 
(P < 0.0001 versus baseline). The EPI group showed a 5.3 ± 6.5% 
decline in fractional shortening. Similar to previous reports from 
our group8, transplantation of only CMs preserved cardiac func-
tion over the 4-week period, indicating that CM transplantation 
prevented the progression to heart failure. Notably, animals receiv-
ing combined CM + EPI grafts showed a 4.5 ± 3.6% improvement 
in fractional shortening, indicating that cotransplantation signifi-
cantly improved left ventricular function (P = 0.0175 versus CMs 
only). Furthermore, we demonstrated that in the CM and CM + EPI 
groups improvements in left ventricular function correlate linearly 
with graft size (Supplementary Fig. 15c).
Comparing pre- and postinjection values, left ventricular end 
systolic dimension (LVESD) remained stable in the CM + EPI group 
and increased in the CM only group, followed by greater increases 
in the EPI and the vehicle control group. The change in LVESD in 
the CM + EPI group was significantly smaller than in the vehicle 
control group but the difference to the CM only group or the EPI 
group did not reach statistical significance (Fig. 5d,e). For left ven-
tricular end diastolic dimension (LVEDD), analysis of variance 
(ANOVA) did not yield a significant difference (Fig. 5f,g). Taken 
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Fig. 3 | Cotransplantation of hESC-EPIs with CMs promotes microvascular density. a, Schematic of study design. b, Representative picrosirius red/fast-
green counterstained infarcted rat heart sections. c, Quantification of myocardial infarct size. N = 37 in total for histologic analysis of infarct size at the 
1-month time point. n represents the number of animals. d, Schematic of areas assessed for vascularization. e, Microvascular density in cardiac grafts. 
f, Microvascular density in the infarct zone. g, Microvascular density in the non-injured border zone of the infarct. Due to the presence of erythrocyte 
autofluorescence all quantification was performed manually to avoid erroneous detection with automated software. Mean values; error bars represent s.d. 
Two-sided P values were calculated using a one-way ANOVA with post-hoc correction for multiple comparisons unless otherwise stated. N = 36 in total for 
histologic analysis at the 1-month time point since 1 animal in the CM group did not exhibit a cardiac graft. Control, EPI, CM and CM + EPI, n = 9, 10, 8 and 
9 animals. Scale bars, 50 μm. I/R, ischemia/reperfusion.
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Fig. 4 | hESC-EPIs potentiate cardiac regeneration. a, Representative sections of infarcted hearts demonstrating the cardiac grafts in animals that received 
either hESC-EPIs and CMs or CMs alone. βMHC is specific for grafted human CMs while αAct antibody stains both rat and human CMs. Scale bar, 2.5 mm. 
b, Quantification of cardiac graft size. c, Proliferative index of human CMs in cardiac grafts. Scale bar, 20 μm. d, Quantification of proliferative index.  
e, Isoform switch of ssTnI to cTnI in CMs in vivo in animals receiving EPI + CM and CM alone. Staining performed in five animals per group. Scale bars, 
20 μm. f, Quantification of sarcomeric length. g, Quantification of cell diameter in CMs in vivo. h, Quantification of cell sectional area in CMs in vivo.  
i, Cardiac grafts and Cx43+ gap junctions with host tissue. Scale bars, 50 μm for i and 20 μm for * and **. i, CX43 staining was performed on all animals. 
Mean values; error bars represent s.d. Two-sided P values were calculated using an unpaired t-test unless otherwise stated. N = 17 in total for histologic 
analysis of cardiac grafts after 1 month; CM and CM + EPI, n = 8 and 9 animals.
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with CMs leads to a greater increase in cardiac function compared 
with transplantation of CMs alone. Furthermore, this benefit mani-
fests principally as enhanced systolic function rather than impact-
ing left ventricular remodeling.
To investigate whether these effects would be present in the 
long term, we followed a subset of 4–5 animals per group for up 
for 3 months. Three months after cell grafting, hESC-EPIs as well 
as hESC-derived CMs were still present in the infarct zone as con-
firmed by anti-human mitochondrial staining (Supplementary Fig. 
16a–c). In line with the 28-d follow-up, at 84 d post-transplantation 
no differences were found in infarct size between the 4 study groups 
(Supplementary Fig. 16d). Functional analysis demonstrated long-
term perpetuation of benefits perceived at 1 month due to persistent 
systolic improvement. Fractional shortening showed no decline in 
animals receiving CM + EPI or CM only but a significant decline 
in animals receiving either EPI or vehicle control. While there was 
no difference in the change of fractional shortening between day 28 
and day 84 among the groups, the change occurring between day 4 
and day 84 was significantly greater in the CM + EPI group com-
pared with CMs only, EPIs only or vehicle control (Supplementary 
Fig. 16e,f). Indeed the 4.5% improvement in fractional shortening at 
4 weeks for epicardial cell cotherapy over CMs alone increased fur-
ther to 9.6% by 12 weeks (Supplementary Fig. 16f). To summarize, 
hESC-derived cellular grafts and related functional improvement in 
cardiac function persist in the long term.
RNA sequencing reveals the epicardial secretome. Finally, to 
address the question of putative mediators of epicardial cell-driven 
cardiac repair we performed RNA sequencing of hESC-derived 
epicardium as used for all in  vitro and in  vivo experiments. In 
embryonic heart development, the neural crest is essential for 
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Fig. 5 | Cotransplantation of epicardial cells and CMs promotes functional recovery. a, Schematic of study design and timing of echocardiographic data 
collection. b, Echocardiographic effects of hESC-EPI augmented cardiac grafts on postinfarct ventricular function. Fractional shortening values are given for 
the 96 h pretreatment baseline and 1-month follow-up. c, Difference in fractional shortening. d, LVESDs are given for the 96 h pretreatment baseline and 
1-month follow-up. e, Difference in LVESD. f, LVEDDs are given for the 96 h pretreatment baseline and 1-month follow-up. g, Difference in LVEDD. Mean 
values; error bars represent s.d. Two-sided P values were calculated using a paired t-test for comparison of cardiac function within groups between baseline 
and 1-month follow-up. If more than two groups were compared, a one-way ANOVA with post-hoc correction for multiple comparisons was used. N = 56 in 
total for functional analysis after 1 month; control, EPI, CM and CM + EPI, n = 13, 15, 14 and 14 animals. EP, endpoint.
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lineage-tracing studies have to date not suggested a role in car-
diac maturation37–39. We first used hESC-derived neural crest cells 
in 3D-EHTs, demonstrating the inability of this cell population to 
result in structural and functional heart maturation, in contrast to 
epicardial cells (Supplementary Fig. 17a,b). We therefore used neu-
ral crest cells as a negative control for RNA sequencing (Fig. 6a and 
Supplementary Table 2).
As epicardial cells resulted in stark effects on tissue remodeling 
of 3D-EHTs and because it has been demonstrated that the extra-
cellular matrix (ECM) plays a key role in epicardial-driven heart 
repair, we focused on ECM molecules secreted by epicardial cells 
and differentially expressed in the hESC-derived neural crest cells 
(Supplementary Table 2). The heatmap shown in Fig. 6a displays dif-
ferentially expressed genes with an adjusted P < 1 × 10−7 (a complete 
list of the genes and their expression is shown in Supplementary 
Table 2). Amongst them, fibronectin is one of the most differentially 
expressed candidates. We then performed a gene ontology enrich-
ment analysis, which further highlights a potential role for ECM 
expressed by hESC-EPIs in myocardial development and matura-
tion (Fig. 6b,c and Supplementary Fig. 18).
We first demonstrated that fibronectin was also abundantly 
expressed at the protein level in 3D-EHTs containing epicardial cells 
but to a lesser degree in constructs containing hESC-MSCs, primary 
MSCs or CMs alone (Fig. 6d). Furthermore, fibronectin was highly 
expressed in cardiac grafts in vivo in animals receiving epicardial 
cells and CMs or epicardial cells alone, but only at a rudimentary 
level in those receiving CMs alone or vehicle control (Fig. 6e). In 
summary, RNA sequencing has provided the secretome of hESC-
derived epicardium and identified a potential involvement of ECM 
remodeling in the process of cardiac maturation in vitro and in vivo. 
These data provide a valuable target library for future cardiac 
repair strategies.
Discussion
This study was designed to address two gaps in knowledge: the 
immaturity of hPSC-derived CMs, and the inefficient remuscu-
larization of infarcts following hPSC-CM transplantation. Because 
of the key trophic role played by the epicardium during develop-
ment, we hypothesized that hPSC-epicardial cells would promote 
CM proliferation and maturation, resulting in better EHT for-
mation in  vitro and better infarct remuscularization in  vivo. We 
found that hESC-EPIs undergo EMT to fibroblast-like cells both 
in vitro and in vivo. In EHTs EPDCs augment tissue structure and 
function, resulting in increased CM size, sarcomere length and 
force production, and augmented Ca2+ handling. When codeliv-
ered with hESC-CMs into myocardial infarcts, EPDCs stimulate 
hESC-CM proliferation, increasing remuscularization by 2.6-fold. 
Additionally, EPDCs stimulate vascularization within the graft and 
infarct scar and in the border zone host myocardium. These changes 
are accompanied by remodeling of the ECM, including high levels 
of fibronectin deposition. Finally, codelivery of hESC-derived epi-
cardium with hESC-CMs results in significantly improved ventricu-
lar function postinfarction.
The pivotal role of the epicardium in heart development is well 
recognized. During early embryonic heart formation the epicardial 
tissue gives rise to coronary smooth muscle cells22,23 and myocardial 
fibroblasts24,25,40. While smooth muscle cells are critical for forma-
tion of the coronary vasculature, cardiac fibroblasts are essential 
for myocardial proliferation and compaction26. Conversely, inhib-
iting proepicardial outgrowth results in pathologic formation of 
the coronary vessels and non-compaction cardiomyopathy41. The 
trophic effect of quail and rat EPDCs has been demonstrated in 
coculture experiments resulting in structural and functional matu-
ration of CMs27,29. Our data show that coculture of hESC-EPIs and 
CMs results in compaction and structural as well as functional 
maturation of 3D-EHT. More specifically, we demonstrate that 
hESC-derived epicardium outcompetes both hESC-derived MSCs 
as well as primary MSCs in terms of force generation and Ca2+ 
handling, corroborating the functional role of its embryonic iden-
tity. The functional potency of epicardial cells might prove broadly 
applicable to current tissue engineering strategies, which would 
benefit from enhanced structural integrity and function of CMs42.
In neonatal mice and in zebrafish, the epicardium is thought 
to have a key role in facilitating myocardial regeneration follow-
ing injury43,44; in contrast, the adult mammalian heart displays 
inadequate epicardial activation and fails to regenerate myocar-
dium postinjury. In this context it has been demonstrated that 
embryonic cardiac fibroblasts induce greater cardiac proliferation 
than their adult counterparts26. Consequently, we propose that 
the fetal-stage epicardium generated by hESCs may preferentially 
promote regeneration.
It is important to consider the mechanism of action through 
which the epicardial cells improve the impact of CM transplantation. 
Since CMs are already effective by themselves, the 2.6-fold enhance-
ment of CM engraftment induced by epicardial cell codelivery may 
underlie much of the benefit on cardiac function. The positive 
correlation of cardiac graft size and percentage change in frac-
tional shortening corroborates this interpretation (Supplementary 
Fig. 15c). Most of this increase in engraftment can be accounted for 
by the twofold increase in CM DNA synthesis rates induced by epi-
cardial cell codelivery, although beneficial effects on CM survival 
cannot be ruled out. Another important factor, however, is that the 
EPDCs induced a substantial amount of angiogenesis in the graft, 
infarct scar and border zone host myocardium. Increased vascular-
ization should improve the function of both graft and host tissues 
and could contribute to the beneficial effect.
A third potential mechanism was raised by our RNA-sequencing 
studies, which demonstrated that hESC-EPIs synthesize an embry-
onic ECM that is particularly rich in fibronectin. It has been demon-
strated that the secretion of fibronectin by epicardial cells is required 
for heart regeneration in zebrafish45. In line with these findings it 
was demonstrated that the orchestrated secretion of fibronectin, 
collagen and heparin-binding EGF-like growth factor by embryonic 
but not adult fibroblasts resulted in CM proliferation26. We therefore 
propose that the matrix laid down by hESC-EPIs is likely to exhibit 
developmental cues that are absent in mature postinfarct myocar-
dium, providing an advantageous niche in a hostile environment; 
the gene ontology analyses of RNA-sequencing data are in support 
of this. Further elucidation of the observed cross-talk between epi-
cardium and CMs might aid ongoing tissue engineering and cell 
therapy endeavors, and the extensive data on epicardially expressed 
genes made available here provide a rich resource for further study. 
These mechanisms are not mutually exclusive and could coexist.
Finally, although we favor the notion that the salutary effects of 
codelivering CMs plus epicardial cells result from the impact on 
CM graft size, vascularization and ECM, we cannot rule out a para-
crine effect from simply increasing the number of delivered cells 
in the combined cell group. Indeed, our data do not permit distin-
guishing the direct mechanical effects of the CM grafts from the 
paracrine factors they secrete; presumably, both mechanisms may 
coexist and be augmented by larger CM grafts. However, this does 
not detract from our primary conclusion that hESC-EPIs recapitu-
late their embryonic role in the post-myocardial infarction setting 
by promoting hESC-derived CM proliferation and maturity and at 
the same time favorably influencing host tissue regeneration.
Two other studies have demonstrated that human primary epi-
cardial cells improve function of the infarcted heart and that cotrans-
plantation of adult cardiovascular progenitors with epicardial cells 
exerts a synergistic effect that exceeds that of monotherapy33,46. 
There were several important differences with our study, includ-
ing their use of epicardial cells and cardiac progenitor cells derived 
from the adult human heart (versus our use of hESC derivatives) 
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Fig. 6 | Epicardial secretome. a, Heatmap depicting differentially expressed secreted factors in epicardial cells compared with neural crest. b, Gene 
enrichment analysis showing the top enriched gene ontology biological processes. The 705 genes specifically enriched in the EPI secretome were 
subjected to a hypergeometric test against a background of the 2,413 secretome genes expressed in NC or EPI. Gene ontology terms are shaded between 
black and white based on their false discovery rate after Benjamini–Hochberg correction. c, Circular gene ontology plot depicting the top gene ontology 
terms enriched in EPI versus NC associated with at least ten genes on the right and the associated genes on the left. Genes are shaded between black 
and white based on their fold enrichment in EPI compared with NC. a–c, EPI and NC, n = 3 and 3. d, Fibronectin expression in 3D-EHT in vitro. CM alone, 
CM + hESC-MSC, CM + Primary MSC and CM + hESC-EPI, n = 9, 9, 8 and 9 constructs, generated independently. Scale bars, 50 μm. e, Fibronectin 
expression in epicardial and cardiac grafts in animals in vivo. Scale bars, 50 μm. This staining was performed on all animals at the 1-month time point 
(n = 37). NC, neural crest. FC, fold change; FDR, false discovery rate.
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and their use of NOD-SCID mice with permanent coronary liga-
tions (versus our use of athymic rats with ischemia-reperfusion 
injury). While these results demonstrated a beneficial effect of poly-
cell therapy, the authors did not detect stable grafts in any of the 
groups, indicating that the effects seen were paracrine in nature. 
Indeed, we are not aware of any studies in the literature that have 
demonstrated robust CM and supportive cell-type engraftment 
in the long term following myocardial infarction. In contrast, our 
grafts, both cardiac as well as epicardial, and related functional ben-
efits were detectable up to 3 months post-transplantation, provid-
ing evidence for longevity and potential perpetuation of benefits in 
the long term.
In conclusion, hESC-EPIs are a promising tool to advance regen-
erative cardiovascular medicine, including cell transplantation as 
well as tissue-engineering strategies. Future studies are warranted to 
better understand the mechanisms through which epicardial cells 
propagate the observed benefits and to investigate their function in 
models that more closely match clinical application.
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Methods
Preparation of hESC-EPIs and hESC-derived CMs. Epicardial cells were 
differentiated from GFP-transgenic hESCs as previously described12. Briefly, 
hESCs (H9, WiCell) were maintained in a chemically defined medium (CDM-
BSA) containing Activin-A (10 ng ml−1, R&D Systems) and FGF2 (12 ng ml−1, 
R&D Systems). Chemically defined medium consisted of IMDM (250 ml, Life 
Technologies), Ham’s F12 (250 ml, Life Technologies), Pen/Strep (5 ml, Life 
Technologies), Insulin (350 μl, Roche), Transferrin (250 μl, Roche), chemically 
defined 100x lipid concentrate (5 ml, Life Technologies) and monothioglycerol 
(20 μl, Sigma). Differentiation to lateral mesoderm was performed as previously 
described in CDM-PVA, containing polyvinyl alcohol (PVA, 1 mg ml−1, Sigma)48. 
In brief, early mesoderm differentiation was started with a combination of 
CDM-PVA, FGF2 (20 ng ml−1), LY294002 (10 μM, Sigma) and BMP4 (10 ng ml−1, 
R&D Systems) for 1.5 d. Then, lateral mesoderm differentiation was started 
in CDM-PVA, FGF2 (20 ng ml−1) and BMP4 (50 ng ml−1) for 3.5 d. To induce 
epicardial differentiation, cells were resuspended as single cells in CDM-PVA, 
WNT3A (25 ng ml−1, R&D Systems), BMP4 (50 ng ml−1) and retinoic acid (4 μM, 
Sigma) at a seeding density of 2.5 × 104 cm−2 for 10 d, and the medium was changed 
halfway through the differentiation. To generate epicardium-derived fibroblasts, 
epicardial cells were replated as single cells at a seeding density of 2.5 × 104 cm−2 
and were grown under the influence of VEGF-B (50 ng ml−1, Peprotech) and 
FGF2 (50 ng ml−1) for 12 d. Flow cytometry was performed on day 10 epicardial 
cells using TCF21 (HPA013189, Atlas Antibodies) and WT1 (Ab89910, Abcam) 
antibodies on a BD FACS Calibur (BD Bioscience) and analyzed using FlowJo VX 
software version 9.9.4 (Fig. 1, panel b, and Supplementary Figs. 8 and 19).
For derivation of mesenchymal stem cells from hESCs, colonies were passaged, 
resuspended in CDM-PVA containing FGF2 (12 ng ml−1) and SB431542 (10 μM) 
and seeded at a density of 30 colonies per cm2 on gel-MEF-coated plates. Cells were 
enzymatically dispersed and passaged 4 times in CDM-PVA containing  
FGF and SB431542 before being split 1 more time in DMEM-F12 containing  
10% fetal bovine serum for long-term maintenance. Primary mesenchymal stem 
cells (gift from Osiris) were also maintained in DMEM-F12 containing 10% fetal 
bovine serum.
CMs were generated from hESCs with the ABCX method as previously 
described49,50. In brief, hESCs (RUES2, female line, Rockefeller University, National 
Institutes of Health (NIH) registry number 0013) were maintained in feeder-free 
irradiated mouse embryonic fibroblast-conditioned medium containing bFGF 
(4 ng ml−1, Peprotech). Cells were seeded as single cells (1 × 105 cm−2) on matrigel 
(BD Biosciences)-coated plates with conditioned medium including Chiron 99021 
(1 μM, Cayman Chemical) and ROCK inhibitor (Y-27632). The following day (day 
0), the medium was aspirated and cells were fed with RPMI medium supplemented 
with B27 (Invitrogen) containing Activin-A (100 ng ml−1) for 18 h. On day 1, 
medium was aspirated and cells were fed with RPMI medium plus B27 containing 
BMP4 (5 ng ml−1) and Chiron 99021 (1 μM) for 48 h. On day 3, medium was 
aspirated and replaced with RPMI medium plus B27 containing Xav 939 (1 μM, 
Torcis). On day 5, the medium was replaced with RPMI medium plus B27. On day 
7, the medium was replaced with RPMI containing B27 with insulin (Invitrogen) 
and was consequently replaced every other day until termination of the protocol.
CMs were frozen down on day 21 and the same batch was used for the entirety 
of the study. Flow cytometry was performed on thawed cells using cTnT antibody 
(Thermo, MS-295-P) on a BD FACSCanto II (Beckton Dickinson) and analyzed 
using FACSDiva software (BD Biosciences), revealing a purity of 97.1 ± 0.5% 
(cTnT+, Fig. 1, panel b).
Epicardial cells were heat-shocked on the day before cell transplantation and 
CMs before freezing, both for 30 min at 42.5°C. On the day of cell transplantation, 
epicardial cells and CMs were enzymatically dispersed, counted and resuspended 
in 100 μl volume per rat of matrigel and prosurvival cocktail (PSC). PSC consisted 
of 50% (vol/vol) matrigel and ZVAD-FMK (100 μM, Calbiochem), Bcl-XL (50 nM, 
Calbiochem), Cyclosporin A (200 nM, Wako Pure Chemicals), Pinacidil (50 μM, 
Sigma) and IGF-1 (100 ng ml−1, Peprotech). Cell preparations either contained 
matrigel plus PSC as vehicle controls, or 5 × 106 epicardial cells, 10 × 106 CMs or the 
combination of 5 × 106 epicardial cells and 10 × 106 CMs in matrigel/PSC.
Mycoplasma screening was performed on all cells on a regular basis and found 
to be negative.
Generation and functional assessment of 3D-EHT. To cast the tissue constructs, 
wells were fabricated using polydimethylsiloxane (PDMS) (Sylgard 184, Dow 
Corning). PDMS linker and base were mixed in a 1:10 mass ratio and poured in 
laser-etched acrylic negative templates featuring 4 wells measuring 3 × 8 × 2 mm3 
and containing a 1-mm-diameter post positioned at 1.5 mm from each end. 
The PDMS was baked at 65 °C overnight, removed from the negatives and then 
autoclaved. Before casting the tissues, the PDMS wells were treated with 5% 
pluronic acid F127 solution (P2443, Sigma) for 1 h.
CMs used for construct studies were frozen down on day 21 of the 
differentiation and given 5 d in culture to recover. During construct casting, CMs 
and epicardial cells were trypsinized and mixed in a collagen gel containing 10x 
RPMI-1640 medium (Sigma), NaOH, geltrex (A1413202, Invitrogen), Collagen I 
Rat Protein (A1048301, Gibco Life Technologies) and water. The cell-gel solution 
was poured into the PDMS wells and allowed to solidify for 30 min at 37 °C. Each 
construct contained either 5 × 105 CMs alone or 5 × 105 CMs plus 5 × 104 supportive 
cells. Constructs were then fed with 7 ml RPMI medium plus B27 plus insulin 
every other day, and spontaneous contractions were observed within 7 d. All 
constructs were cultured for 14 d, fixed with 4% paraformaldehyde, treated with 
30% sucrose at 4 °C overnight and finally cryoembedded and sectioned.
Myofibril alignment was quantified using an orientation correlation function 
(OCF) as previously described51: OCF = 0.5 (cos(2θ) + 1), where θ is the difference 
between the angle of the myofibril fibril and the longitudinal CM axis.
For assessment of Ca2+ handling, 14-day-old constructs were incubated with 
fluo-4, AM (Molecular Probes, Invitrogen) for 20 min at 37 °C. Videos were taken 
with a Sony Handycam (Vixia HFS20) attached to a fluorescence microscope 
(Nikon Eclipse TS100). Videos were subsequently converted to frames, imported 
and analyzed using Image J software, normalizing the Ca2+ signal to baseline.
Force measurement of constructs was performed after 2 weeks in culture as 
previously described52. In brief, constructs were removed from the PDMS wells 
and suspended between a force transducer (model 400A, Aurora Scientific) and 
length controller (model 312B, Aurora Scientific). To assess the Frank–Starling 
relationship, constructs were stretched from their resting length to an additional 
25% strain in 6 steps while being bathed in a HEPES-buffered Tyrode solution 
held at 37 °C. Force traces were first recorded without electrical stimulation and 
subsequently with 1, 1.5, 2 and 3 Hz at 5 V and 50 ms pulse duration. Passive 
tension and active force traces were recorded and analyzed using customized 
LabView and MATLAB software. A total of nine independent constructs were 
generated for each group and used for morphometric and functional analysis. The 
only exclusion criterion was tissue damage of the integrity of the loop regions. 
CMs were used from one frozen batch to ensure constant ultra-high purity and 
epicardial cells were used from three different differentiations.
Gene expression analysis. EHTs were dissociated and gene expression analyses 
performed after 2 weeks in culture. Total cellular RNA was extracted with 
ARCTURUS PicoPure RNA Isolation Kit (KIT0103, Applied Biosystems) with the 
following modifications. EHTs were placed in Lysing Matrix D beads (116913050, 
MP Biomedicals) and 200 µl Extraction Buffer and homogenized using a 
FastPrep-24 5G Instrument (MP Biomedicals). The resulting lysate was transferred 
to a fresh tube and incubated at 42 °C for 30 min. Then, 70% ethanol was added 
to the RNA lysate and loaded into a preconditioned column. All subsequent steps 
were performed according to the supplier’s recommendations, including DNase I 
treatment. Next, 10 µl eluted RNA (corresponding to 100–150 ng) was subjected to 
reverse transcription using Maxima First Strand kit (K1641, Thermo) according 
to the manufacturer’s protocol. RT–qPCR was performed with Fast SYBR Green 
Master Mix (4385610, Thermo) using 5 ng complementary DNA and 100 nM 
forward and reverse primers. Reactions were run on a 7900HT Fast Real-Time 
PCR System (4329001, Applied Biosystems), and data were analyzed using the 
ΔΔCt method using HPRT1 as the housekeeping gene. Primers were designed 
using PrimerBlast and confirmed to amplify a single product. A complete list is 
provided in Supplementary Table 3.
Injection of hPSC-derived epicardial cells in chicken embryos. Chicken 
(Gallus gallus domesticus) eggs (Winter Egg Farm) were incubated in a digital 
cabinet incubator (OVA Easy 380, Brinsea) at 38 °C. At Hamburger Hamilton 
developmental stage 19 (HH19), the eggshell was fenestrated, the window was 
covered with parafilm (VWR) and the eggs were placed horizontally in the 
incubator. At HH35, epicardial cells were transplanted in PSC with matrigel (1:2 
dilution) onto the chorionic chicken vasculature. HESCs were fully differentiated 
to epicardial cells before administration into the chicken embryos. The eggs were 
then returned to the incubator until stage HH40. The matrigel plugs were collected 
and fixed in 4% paraformaldehyde before being stained with anti-HLA1 (Abcam), 
anti-SM22alpha (Abcam) and Sambucus nigra lectin (Vector Laboratories).
Myocardial infarction and cell transplantation. All studies were approved by 
the University of Washington Animal Care and Use Committee (protocol number 
2225-04) and were conducted in accordance with US NIH Policy on Humane 
Care and Use of Laboratory Animals. The study design comprised two feasibility 
studies and one definitive study. The first study was designed to assess the acute 
survival and fate of hESC-EPIs. Animals either received 2 × 106 (n = 4) or 4 × 106 
(n = 4) epicardial cells or a vehicle control injection (n = 4). In a second feasibility 
study, designed to assess long-term survival of epicardial cells and their function, 
animals randomly received either 6 × 106 epicardial cells (n = 6) or a vehicle control 
injection (n = 4). The definitive study was conducted to assess the trophic effect 
of the epicardium on CMs. The definitive study design comprised the following 4 
study arms: 5 × 106 epicardial cells (n = 15), 10 × 106 CMs (n = 14), 5 × 106 epicardial 
cells plus 10 × 106 CMs (n = 14) and vehicle control (n = 13). Animal deaths and 
cellular engraftment are presented in Supplementary Table 4.
The protocol for cell implantation has been previously detailed8,34. In brief, 
male athymic Sprague Dawley rats (Harlan/Envigo) underwent anesthesia through 
intraperitoneal injection of 68.2 mg kg−1 ketamine and 4.4 mg kg−1 xylazine, and 
were intubated and mechanically ventilated with room air and supplemented 
oxygen. A second dose of ketamine and xylazine was administered 20 min later. 
Animals were placed on a heating pad connected with a rectal temperature 
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probe, which ensured maintenance of body temperature at 37 °C. A thoracotomy 
was subsequently performed, the anterior surface of the heart was exposed and 
the left anterior descending coronary artery was visualized. The left anterior 
descending coronary artery was consequently ligated for 60 min after which the 
ligation was removed, the animal reperfused and the chest aseptically closed. At 
4 d post-myocardial infarction, animals were anesthetized with isoflurane before 
undergoing a second thoracotomy for intramyocardial cell transplantations. 
Animals were subsequently randomly assigned to one of the treatment groups and 
cells were injected into the infarct zone. The chest was subsequently closed and the 
animals were postoperatively monitored.
To optimize graft retention, animals received daily subcutaneous injections of 
5 mg kg−1 Cyclosporine A from the day before surgery until 7 d after the surgery. 
To assess cell proliferation in the cell grafts, animals were injected with 50 mg kg−1 
BrdU on days 1, 4, 7 and 14 post-cell injection. The cohort of animals that was 
followed up for 3 months additionally received 1 BrdU injection 24 h before the 
termination of the study.
Echocardiography. All animals underwent echocardiographic exams at baseline 
before myocardial infarction, 4 d after the infarct and 28 d after cell transplantation. 
A subset of animals were maintained and imaged at 84 d post-transplantation. 
Briefly, animals were lightly anesthetized with inhaled isoflurane (Novaplus) and 
scanned by transthoracic echocardiography (GE Vivid 7) using a 10 S (10 MHz) 
pediatric probe. The end points acquired comprised fractional shortening (%), 
LVEDD and LVESD. LVDD and LVESD are expressed in millimeters. The images 
were anonymized and a primary reader made measurements in a blinded manner. 
For validation purposes an independent investigator analyzed a sample set of 
images in a blinded fashion before analysis of the entire data set and at the end 
to ensure consistency in measurements. The respective Bland–Altman plots and 
intraclass correlation coefficients of these two tests are presented in Supplementary 
Fig. 20. Details of histologic and echocardiographic parameters are presented in 
Supplementary Table 1.
Immunocytochemistry and immunohistochemistry. For immunocytochemistry, 
cells were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 
in PBS and blocked in 3% BSA/PBS for 45 min at room temperature. Primary 
antibody incubations were performed at 4 °C overnight. The next day, cells were 
washed and incubated with Alexa-Fluor-conjugated secondary antibodies for 
45 min at room temperature before staining with 4,6-diamidino-2-phenylindole 
(DAPI) for 10 min to visualize the nuclei. For immunohistochemistry, hearts 
were excised postmortem and prepared as described34. Briefly, hearts were 
washed in PBS, kept in saturated KCl for 20 min and subsequently fixed in 4% 
paraformaldehyde and paraffin sectioned (5 mm). For immunohistochemistry 
stainings, slides were deparafinized, underwent heat-mediated antigen retrieval  
for 15 min and were blocked with 5% BSA/PBS containing 0.3% Triton X-100  
for 1 h at room temperature, followed by incubation with primary antibodies 
at 4 °C overnight, and fluorescent secondary antibodies were applied at 
room temperature for 60 min on the consecutive day. All antibodies used for 
immunocytochemistry and immunohistochemistry studies are detailed in 
Supplementary Table 5.
For quantification of sarcomeric length, a total number of 1,271 sarcomeres 
(129 CMs) were quantified in vitro (9 constructs) and 4,660 sarcomeres (407 CMs) 
were quantified in vivo (37 animals) by manual measurements in a blinded fashion.
Infarct and graft quantification. To assess infarct size, slides were stained with 
picrosirius red/fast-green stain. Subsequently, in the infarcted sections, picrosirius 
red-positive area was quantified and normalized to the left ventricular area in 
each section. For quantification of cardiac graft size, slides were stained overnight 
with human mitochondria antibody (Novus) and α-Actinin (Abcam) to quantify 
the size of the human cardiac grafts, followed by 1 h incubation with Alexa 
Fluor-488 donkey anti-rabbit and Alexa Fluor-568 goat anti-mouse secondary 
antibodies (Invitrogen). The corresponding graft size was then normalized to 
the size of the infarct area. All animals were used for analysis except one animal 
in the CM only study arm, which did not exhibit a detectable graft. Images were 
acquired on a Nikon TiE Inverted Widefield Fluorescence High-Resolution 
Microscope. To assess epicardial grafts, anti-GFP (Novus) and anti-human 
mitochondria (Novus) antibodies were used. For investigation of EMT of grafted 
epicardial cells, slides were stained with antibodies directed against GFP (Novus), 
vimentin (Dako) and wide-spectrum cytokeratin (Dako). To determine the 
fate of epicardial cells, slides were costained with antibodies directed against 
human mitochondria (Novus) and CMs (alpha-Actinin, Abcam), endothelial 
cells (human lectin (Ulex europaeus, Vector)), smooth muscle cells (Smooth 
Muscle α-Actin, Dako) or fibroblasts (S100A4, Abcam). To detect cardiac grafts, 
antibodies directed either against human mitochondria and α-Actinin or against 
β-MHC (Developmental Studies Hybridoma Bank) were used. For assessment 
of microvascular density, slides were stained with CD31/PECAM (Novus) and 
either β-MHC (Developmental Studies Hybridoma Bank) or cTnI (Abcam). For 
quantification of microvascular density in cardiac grafts, the infarct zone and 
the non-injured border zone, nine high-power images were taken in each of the 
three areas of interest. The number of lumens was counted and expressed as vessel 
number per area (mm2). All images were acquired in technical replicates per 
animal on a Zeiss LSM700 microscope using ZEN software and were subsequently 
analyzed using ImageJ software. A detailed description of the antibodies and 
dilutions is provided in Supplemental Table 1.
RNA sequencing. The starting material for RNA sequencing was hESC-derived 
epicardium as used for all in vitro and in vivo experiments. For bulk RNA 
sequencing total RNA was extracted with the RNeasy Mini kit according to the 
manufacturer’s instructions (Qiagen). This was followed by RNAse treatment to 
remove contaminating DNA. Samples were consecutively sent to the Genomics 
facility at the Wellcome Trust – Medical Research Council Cambridge Stem Cell 
Institute, where cDNA libraries were generated using the SMARTer Stranded  
Total RNA-Seq Kit.
All samples were sequenced on two lanes of an Illumina HiSeq2500. Short 
reads were mapped to the Homo sapiens genome GRCh38 using HISAT2 (ref. 53).  
For each sample, the bam files corresponding to both lanes were merged with 
bamtools54. These data have been deposited in NCBI’s Gene Expression Omnibus 
and are accessible through GEO Series accession number GSE122714 (ref. 55).
The number of reads per sample varies from 10 million (NC1) to 24 million 
(NC2). Quality control and read count were performed with SeqMonk (https://
www.bioinformatics.babraham.ac.uk/projects/seqmonk/). Differential expression 
analysis between differentiated epicardium and neural crest cells was performed 
with DESeq2 (ref. 56). The list of 8,261 differentially expressed genes was filtered 
to retain: (1) only genes encoding putatively secreted proteins, according to the 
Human Protein Atlas (http://www.proteinatlas.org/humanproteome/secretome 
(ref. 53)); and (2) only genes annotated with the gene ontology term ‘extracellular 
matrix organization’ using QuckGO (https://www.ebi.ac.uk/QuickGO (ref. 57)). The 
heatmap only displays differentially expressed genes with an adjusted P < 1 × 10−7, 
and was performed using the function heatplot of the package made4 on the log2 
of reads per million reads values58. For clustering, heatplot uses Pearson correlation 
distances and the average agglomeration method. The gene ontology enrichment 
was performed with WebGestalt59. A complete list of the genes and their expression 
is shown in Supplementary Table 2.
Statistics. All in vitro studies were performed with three biological replicates 
(independent experiments performed on different days), each of which was 
performed using three technical replicates. All in vivo data specifically state the 
number of animals assessed for each time point. The normal distribution of our 
values was confirmed using the D’Agostino and Pearson omnibus normality test 
where appropriate. Variance between samples was tested with the Brown–Forsythe 
test. Statistical testing was performed using an unpaired t-test for two-group 
comparisons and a paired t-test for comparison of two paired groups. For multiple-
group comparison a one-way ANOVA with a post-hoc Tukey test was used if the 
group variance was equal, and a Kruskall–Wallis test with Dunn’s correction for 
multiple comparisons was applied for groups with unequal variance. Measuring 
two-sided significance, a P value of 0.05 was considered statistically significant. All 
analyses were performed using GraphPad Prism software in a blinded fashion. All 
results are expressed as mean ± s.d., unless otherwise stated.
For all in vivo experiments, group sizes were estimated based on power 
analyses using previous study variance. While no formal methods of 
randomization were used, the animals were randomly selected by a technician who 
was blinded to treatment. Analysis of all histology slides as well of all functional 
data was done in a blinded fashion. Death was the only exclusion criteria for 
further histologic and functional analysis. Supplementary Table 4 details animal 
mortality and grafting.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The raw data that support the findings of this study are available from the 
corresponding author upon reasonable request.
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Antibodies used All antibodies used are listed in supplementary table 5 as follows  
(Antibody; Application; Species; Dilution; Manufacturer (Cat#)): 
 
Vimentin, Clone Vim 3B4; ICC/IHC; Mouse; 1:100; Dako (M7020) 
Cytokeratin; ICC/IHC; Rabbit; 1:150; Dako (Z0622) 
GFP; IHC; Goat; 1:500; Novus (NB-100-1770) 
Human Mitochondria, Clone 113-1; IHC; Mouse; 1:100; Millipore (MAB1273) 
Fibronectin; IHC; Rabbit; 1:250; Abcam (ab2413) 
Alpha-Actinin; IHC; Rabbit; 1:800; Abcam (ab68167) 
Cardiac Troponin I; IHC; Rabbit; 1:200; Abcam (ab47003) 
Cardiac Troponin T; IHC; Goat; 1:200; Abcam (ab64623) 
Cardiac Troponin T;  IHC; Mouse; 1:200; Abcam (ab8295) 
Connexin 43; IHC; Mouse; 1:500; Millipore (MAB3067) 
Connexin 43; IHC; Rabbit; 1:500; Abcam (ab11370) 
Beta-Myosin Heavy Chain, Clone A4.951; IHC; Mouse; Full strength; Human Hybridoma Bank 
CD31/ PECAM-1; IHC; Rabbit; 1:100; Novus (NB100-2284) 
Biotinylated human Lectin; IHC; Ulex europaeus; 1:1000; Vector (B-1065) 
S100A4 ICC; IHC; Rabbit; 1:100; Abcam (ab124805) 
DDR2; ICC; Goat; 1:50; Santa Cruz (sc-7555) 
Smooth Muscle Alpha Actin; IHC; Mouse; 1:200; Dako (M0851) 
Smooth Muscle Alpha Actin; IHC; Goat; 1:200; Abcam (ab21027) 
Anti-BrdU-POD, Clone BMG-6H8; IHC; Mouse; 1:40; Roche (11 585 860 001) 
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SM-22; IHC; Rabbit; 1:400; Abcam (ab14106) 
cTnT; Flow;  Mouse; 1:100; Thermo Fisher (MS-295-P) 
TCF21; Flow; Rabbit; 1:250; Atlas Antibodies (HPA013189) 
WT1;  Flow; Rabbit; 1:500; Abcam (Ab89910) 
Alexa Fluor 647; Flow; Chicken anti Rabbit IgG; 1:200; Invitrogen (A21443) 
Alexa Fluor 488; IHC; Rabbit anti Mouse IgG; 1:100; Invitrogen (A11054) 
Alexa Fluor 488; IHC; Goat anti Mouse IgG; 1:100; Invitrogen (A11001) 
Alexa Fluor 488; IHC; Donkey anti mouse IgG; 1:100; Invitrogen (A21202) 
Alexa Fluor 488; IHC; Donkey anti Goat IgG; 1:100; Invitrogen (A11055) 
Alexa Fluor 488; IHC; Donkey anti rabbit IgG; 1:100; Invitrogen (A21206) 
Alexa Fluor 488; IHC; Rabbit anti goat IgG; 1:100; Invitrogen (A11078) 
Alexa Fluor 488; IHC; Goat anti rabbit IgG; 1:100; Invitrogen (A110034) 
Alexa Fluor 568; IHC; Goat anti mouse IgG; 1:100; Invitrogen (A11031) 
Alexa Fluor 568; IHC; Donkey anti mouse IgG; 1:100; Invitrogen (A10037) 
Alexa Fluor 568; IHC; Rabbit anti mouse IgG; 1:100; Invitrogen (A11061) 
Alexa Fluor 568; IHC; Donkey anti rabbit IgG; 1:100; Invitrogen (A10042) 
Alexa Fluor 568; IHC; Donkey anti Goat IgG; 1:100; Invitrogen (AA21432) 
Alexa Fluor 647; IHC; Donkey anti mouse IgG; 1:100; Invitrogen (A31571) 
Alexa Fluor 647; IHC; Donkey anti goat IgG; 1:100; Invitrogen (A21447) 
Alexa Fluor 647; IHC; Goat anti rabbit IgG; 1:100; Invitrogen (A21244)
Validation The validity of each antibody was tested using positive and negative controls using 4% PFA fixed and paraffin embedded rat 
heart sections or 4% PFA fixed and paraffin embedded human fetal hearts. Control stainings are displayed in the figures.  
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) hESCs (RUES2, Female line, Rockefeller University) & hESCs (H9, WiCell, Madison)  
Authentication Cell lines were obtained directly from the provider. No formal form of authentication was carried out. 
Mycoplasma contamination Mycoplasma screening was performed on the cell lines and was negative.
Commonly misidentified lines
(See ICLAC register)
None of the cell lines used in this study are listed in the ICLAC database. 
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals Male athymic Sprague Daley rats (Harlan/Envigo); age: 8-10 weeks on arrival. 
Wild animals This study did not use wild animals. 
Field-collected samples The study did not involve samples collected from the field. 
Ethics oversight All studies were approved by the University of Washington Animal Care and Use Committee (IACUC; protocol number 2225-04) 
and were conducted in accordance with US NIH Policy on Humane Care and Use of Laboratory Animals. 




The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Cardiomyocytes were frozen down on day 21, thawed and then used for experiments, including flow cytometry, using a standard 
protocol and primary antibodies as follows: TCF21 (Atlas antibodies, HPA013189), WT1 (Abcam, Ab89910) and cTnT antibody 
(Thermo, MS-295-P).
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Instrument Data were collected using: 1) BD FACS Calibur (BD Bioscience) for hESC-epicardial cells and 2) BD FACSCanto II (Beckton 
Dickinson, San Jose, CA) for hESC-cardiomyocytes.  
Software Flow cytometric analysis was performed with FlowJo VX software version 9.9.4. 
Cell population abundance Flow cytometry revealed a purity of 97.1% for hESC-derived cardiomyocytes and a purity of 73.2% for epicaridal cells (Figure 1, 
panel b). 
Gating strategy HESC-derived cardiomyocytes and hESC-derived epicardial cells were used as a starting population. Cells were gated on FSC/SSC 
first and an unstained sample, IgG isotype and secondary only as controls to establish the gate for positive cells.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
